Document:

EX-10.17

 Exhibit 10.17 

[Grant Date] 
 [Name] 

[Address] 
 Re: Non-Employee Director Share Award Confirmation

 Dear [Name]: 
 This letter confirms that you have been
granted a Non-Employee Director Share Award under the Marriott Vacations Worldwide Corporation Stock and Cash Incentive Plan (the “Plan”) for the following number of Shares (as defined in the Plan): 

 

							
	 Number of Shares
	  	 	  	 	  	 
	 [            ]
	  		  		  	

 This Award will be recorded in a book-keeping account and represents your unsecured right to receive from the Company the
transfer of title to the specified number of Shares, as such number may be adjusted pursuant to the Plan, at such time as you have elected by designating in writing to the Company in the manner required by the Company for such election or, if no
such election is made, promptly following Termination of Service (as that term is defined in the Plan). Your right to the Shares is fully vested upon grant. 

Prior to the delivery of Shares to you, (i) your rights under this Award may not be transferred, pledged or hypothecated; and (ii) you will not have
any voting rights in the Shares subject to this Award. In the event a cash dividend is paid with respect to the Company’s common stock, a corresponding dividend equivalent payment will be paid to you in cash as of the payment date for such
dividend. 
 If you have any questions, please feel free to call me at 407-206-6137. 

Sincerely, 
 Catherine M. Peffen, 

Vice President, Global Compensation & Benefits 
 Marriott
Vacations Worldwide CorporationEX-10.26

 Exhibit 10.26 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 AMENDMENT NO.1 

TO 
 SUPPLY AGREEMENT

 This Amendment No. 1 (the “Amendment No. 1”) to that certain supply agreement between Intersect
ENT, Inc., a Delaware corporation having offices at 1555 Adams Drive, Menlo Park, California 94025, and Stephen Gould Corporation, a New Jersey corporation having offices at 45541 Northport Loop West, Fremont, CA 94538 (“the
Agreement”), with an effective date of November 14, 2013, is made as of October 7, 2015 (the “Amendment No. 1 Effective Date”). Unless otherwise defined herein, capitalized terms used in this Amendment
No. 1 have the meanings ascribed to them in the Agreement. 
 RECITALS 

WHEREAS, the parties hereto desire to amend the Agreement in accordance with this Amendment No. 1. 

NOW, THEREFORE, Customer and Supplier hereby agree as follows: 

1. Section 3.2 Quality Agreement is amended as follows: The instance of October 2013 in the third line is deleted and replaced with
October 7, 2015. 
 2. Section 11.9 Entire Agreement Amendment is amended as follows: The date September 16, 2015 is inserted into the
fifth line at the end of the bracketed clause and the brackets and bold-faced type are removed so that the clause reads: Confidential Disclosure Agreement between the Parties dated September 16, 2015. 

3. EXHIBIT A “PRODUCTS/PRICE LIST” is deleted in its entirety and replaced with the following: 

 

							
	 Part number and Name
	  	Price per
Unit	  	3 Month
Forecast	  	 Annual

Forecast

	 [*]
	  	[*]	  	[*]	  	[*]

  
 -1- 

 4. Governing Law. Any claim, dispute, or controversy of whatever nature arising out of or relating
to this Amendment No. 1 shall be governed by and construed under the laws of the State of California, without giving effect to any choice of law principles that would require the application of the laws of a different state or country. 

5. Continued Effectiveness of the Agreement. Except as set forth in this Amendment No. 1, the provisions of the Agreement are not amended
or modified in any way and continue in full force and effect in accordance with their terms and conditions. 
 6. Amendment. This Amendment
No. 1 may be amended only upon the written consent of the Members. 
 7. Counterparts. This Amendment No. 1 may be executed in one
or more counterparts, each of which will be deemed an original but all of which together will constitute one and the same instrument. Any signature page delivered electronically or by facsimile (including, without limitation, transmission by .pdf or
other fixed image form) will be binding to the same extent as an original signature page. 
 In Witness Whereof, the Parties hereto
have duly executed this Agreement on the Effective Date. 
  

									
	INTERSECT ENT, INC.	 		 	STEPHEN GOULD CORPORATION
					
	By:	 	/s/Daniel Castro	 		 	By:	 	/s/Vance Garland
	Name:	 	Daniel Castro	 		 	Name:	 	Vance Garland
	Title:	 	Vice President Operations and Mfg. Eng.	 		 	Title:	 	Project Manager

  

  
 -2- 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.EX-10.28

 Exhibit 10.28 
  

					
	 Exova
 2395 Speakman Dr.

Missisauga
 Ontario

Canada
 L5K 1B3

 
 Testing. Advising. Assuring
	  	 T: +1 (905) 822-4111
 F: +1 (905)
823-1446
 E: sales@exova.com
 W: www.exova.com
	  	

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

Analytical testing Partnership Program 2016-2017 
  

			
	Quotation to:	 	 Intersect ENT
 1049 Elwell Court

Palo Alto CA 94303
 USA

		
	Attention:	 	 Xiaoyi Hu
 Manager CMC and Analytical
Services
 650-641-2111
 xhu@intersectENT.com

		
		 	 Rich Kaufman
 Chief Operating Officer

650-641-2107
 rkaufman@intersectENT.com

		
	Quotation Number:	 	 15-011-383926
 7 Pages

		
	Date:	 	October 05, 2015

  

					
	 Analytical Testing Partnership Program 2016-2017

For Intersect ENT
	 	 Page 2 of 4

Quotation No.: 15-011-383926
	  	

 

 EXECUTIVE SUMMARY 

Exova’s Health Sciences group has developed a strong relationship with Intersect ENT during the past decade. Over this period, services provided have
included method development, method and process validation, contaminant and unknown investigation, characterization of impurities, raw material and finished product testing, and stability program services. 

Intersect ENT has had major success in product development, clinical efficacy and approval of its novel stent products. The company is experiencing rapid
growth in moving from a purely research organization, to a manufacturing firm with a continuing R&D pipeline. 
 Exova has made investments to increase
our capacity in tandem, so that Intersect ENT can continue to rely on Exova as the vendor of choice for analytical support and development. We appreciate your regular feedback and this has been very valuable in making changes and improvements so
that our final product meets your expectations. 
 Exova is committed to working with Intersect ENT to manage costs and to extend our mutually beneficial
and cost effective long term partnership. In this light, for the next 24 months Exova is pleased to offer a pricing arrangement that includes an annual [*] increase to offset inflationary pressures, but retains the same base pricing structure for
[*] services which has not been altered for the last seven years. 
 We are looking forward to continuing to support Intersect ENT for analytical testing
development and stability needs. 
 Approved by: 
  

					
			
	/s/ Eric Lindsay	 		 	/s/ John McNeill
	 Eric Lindsay
 General Manager

Health Sciences Santa Fe Springs
	 		 	 John McNeill, M.Sc., C. Chem.
 Director
Health Sciences
 Americas

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

					
	 Analytical Testing Partnership Program 2016-2017

For Intersect ENT
	  	 Page 3 of 4

Quotation No.: 15-011-383926
	  	

 

 PRICING 

Table 1. Custom Analyses 
  

					
	 Test Method
	  	Price Structure 2016
[*]	 	Price Structure 2016
[*]
			
	 [*]
	  	[*]	 	[*]

 This 2016 pricing structure includes a [*] inflationary price increase but the base pricing structure remains the same; a [*]
increase will also be applied to the 2017 calendar year beginning January 01, 2017. The pricing indicated in the above table is quoted for [*] (please note: turnaround time is defined as delivery of the final Certificate of Analysis by 5:00 PM
PT on the day promised). 24 and 72 hour priority service will be accompanied by a surcharge of [*]% and [*]%, respectively. 
  

	 	(1)	To assist Exova in making compressed timing commitments, Intersect ENT will work to provide pre-notification whenever possible of upcoming sample submission schedules. 

 

	 	(2)	Raw Data packages are [*] of the total analytical cost, $[*] minimum and $[*] maximum. 

  

	 	(3)	Due to the lengthy nature of this procedure, to ensure that [*] turnaround commitments are consistently met, Intersect ENT will provide five to ten days forewarning of upcoming sample submissions and batch samples
shipments whenever possible. If multiple lots with [*], timeline should be discussed and agreed upon between Exova and Intersect ENT. When [*] analysis is requested for [*], additional samples will be requested by Exova and the results available in
less than five working days from sample receipt. 

  

	 	(4)	This test includes [*] as part of the listed fee as this data will be acquired [*]. 

 [*] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 

  

							
	 Analytical Testing Partnership Program 2016-2017

For Intersect ENT
	  	 Page 4 of 4

Quotation No.: 15-011-383926
	  	 	

 	  

 Table 2. USP/NF/EP/Custom Monograph Testing 

 

					
	 Test Method
	  	Price Structure
2016
[*]	 	Price Structure
2016
[*]
			
	 [*]
	  	[*]	 	[*]

 Raw Data packages are [*] of the total analytical cost, $[*] minimum and $[*] maximum. The pricing indicated in the above
table is quoted for [*] turnaround (please note; turnaround time is defined as delivery of the final certificate of analysis by 5:00 PM PT on the day promised). 24 and 72 hour priority service will be accompanied by a surcharge of [*] and [*],
respectively. 
  

	 	(1)	To ensure that turnaround commitments are consistently met, IntersectENT will provide five to ten days forewarning of upcoming sample submissions and batch sample shipments whenever possible. 

TERMS AND CONDITIONS 
 This quotation is open for
acceptance until December 15, 2015, and these prices will be in effect until December 31, 2017. It can be accepted on or before this date by signing and returning to Exova. After the validity date, Exova reserves the right to revise and/or
withdraw the quotation as appropriate. This quotation has been prepared exclusively on behalf of Exova and is provided in confidence. The contents of this quotation including pricing information is for the sole consideration of Intersect ENT and
cannot be divulged to a third party without the expressed written consent of Exova. 
 This quotation and the services are governed by the terms and
conditions (“the Conditions”) as attached. This quotation may be accepted by signing the enclosed copy in the space provided below and returning it, for receipt by Exova within the time for acceptance given above. It will then constitute
an agreement between us (the “Contract”). Please be advised that a purchase order is acceptable for billing purposes only, and the work is governed by the attached terms and conditions. 

Accepted by Intersect ENT: 
  

							
	 /s/ Richard Kaufman
	 	 Richard Kaufman
	 	 Chief Operating Officer
	 	 10/6/15

	Signature	 	Name	 	Title	 	Date

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]